Page 37 of 346: studies 361 to 370 of 3,454, newest first. Back to the MDMA overview
Routledge eBooks August 11, 2023 Douglas Thomas
BDSM and kink practitioners sometimes describe scenes that induce altered dream-like states with blurred boundaries and vivid transcendent imagery. Firsthand accounts illustrate the intensity and transformational character of such experiences, which can be characterized as ecstatic. The activities of alternative sexualities are a modern iteration of humanity’s archetypal fascination with...
The International Journal of Neuropsychopharmacology August 7, 2023 Apochi Obed Okwoli
Obed Okwoli Apochi, MSc; New study reveals long-term effects of MDMA on the brain's glutamate-glutamine complex, International Journal of Neuropsychopharmacolog
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie August 1, 2023 I-Hsun Li, Tsung-Ta Liu, Ying-Chen Chen et al.
3,4-methylenedioxymethamphetamine (MDMA) is a popular recreational drug, however over 200 studies demonstrate that acute (e.g. hyperthermia, rhabdomyolysis) and chronic (e.g. neurotoxicity) toxicity effects of MDMA were observed in different animals. Methimazole (MMI), an inhibitor of thyroid hormone synthesis, was found to significantly reduce the HSP72 expression of heat stress induced in...
Frontiers in Psychiatry July 15, 2023 M. Kati Lear, Sarah M. Smith, Brian Pilecki et al. 14 citations
BackgroundSocial anxiety disorder (SAD) is a serious and prevalent psychiatric condition that heavily impacts social functioning and quality of life. Though efficacious treatments exist for SAD, remission rates remain elevated and a significant portion of those affected do not access effective treatment, suggesting the need for additional evidence-based treatment options. This paper presents a...
Nature July 13, 2023 Rich Haridy 55 citations
Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed. Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed.
British medical journal July 11, 2023 B. Nogrady 18 citations
The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...
Australian Journal of Chemistry July 11, 2023 Katie D. Lewis, Glenn A. Pullella, Han Chern Loh et al. 2 citations
Homochiral (R)- and (S)-3,4-methylenedioxymethamphetamine (MDMA) were prepared in six steps (each) from the chiral pool precursors d- and l-alanine, respectively. The key step, copper-catalysed regioselective ring-opening of an N-tosylaziridine with an aryl Grignard reagent, proceeded in high yield with complete regioselectivity. Elaboration was achieved with preservation of configurational...
The lancet. Diabetes & endocrinology July 2023 Cihan Atila, Friederike Holze, Rakithan Murugesu et al.
Disruptions of the hypothalamic-pituitary axis can cause an arginine vasopressin deficiency, also known as central diabetes insipidus. Patients with this condition are at high risk of additional oxytocin deficiency owing to the close anatomical proximity of oxytocin-producing neurons; however, no conclusive evidence for such a deficiency has been reported. We aimed to use...
Focus July 1, 2023 Benjamin R. Lewis, Kevin Byrne 9 citations
Posttraumatic stress disorder (PTSD) is a common chronic and disabling psychiatric disorder that may develop after exposure to a traumatic life event. There are existing evidence-based psychotherapies and pharmacotherapies for PTSD; however, these treatments have significant limitations. 3,4-methylenedioxymethamphetamine (MDMA) was granted "breakthrough therapy" status by the U.S. Food and Drug...
FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2023 Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. 97 citations
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...